In recent years, the integration of biophysical techniques with molecular simulations and artificial intelligence (AI) has revolutionized our understanding of biomolecular and cellular properties.

RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14th, 2024, Reviva Pharmaceutical ...

Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...

PSA responses were seen both in patients with androgen receptor wild type (including androgen receptor amplification) and ligand binding domain mutations, the investigators pointed out. No grade 4 ...

Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing ...

Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR ...

Engineered receptors could lead to more precisely targeted, effective cancer therapies with fewer side effects than existing ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash ...

Longer survival was seen in those with melanoma who received programmed cell death receptor-1 or its ligand who had a low neutrophil-lymphocyte ratio.

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...